HC Wainwright Weighs in on Editas Medicine Q3 Earnings

Editas Medicine, Inc. (NASDAQ:EDIT) – Investment analysts at HC Wainwright issued their Q3 2027 EPS estimates for Editas Medicine in a research note issued to investors on Tuesday, May 26th. HC Wainwright analyst M. Kapoor expects that the company will post earnings per share of ($0.34) for the quarter. The consensus estimate for Editas Medicine’s current full-year earnings is ($1.07) per share. HC Wainwright also issued estimates for Editas Medicine’s FY2027 earnings at ($1.15) EPS.

Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings results on Tuesday, May 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.30) by $0.04. The company had revenue of $2.83 million for the quarter, compared to analysts’ expectations of $6.37 million. Editas Medicine had a negative net margin of 281.59% and a negative return on equity of 677.39%.

A number of other brokerages have also recently issued reports on EDIT. Robert W. Baird set a $6.00 price target on shares of Editas Medicine in a research note on Monday, March 9th. Wall Street Zen cut shares of Editas Medicine from a “hold” rating to a “sell” rating in a research note on Sunday, May 10th. TD Cowen reiterated a “buy” rating on shares of Editas Medicine in a research note on Monday, March 9th. Chardan Capital increased their target price on Editas Medicine from $3.50 to $4.00 and gave the company a “buy” rating in a research note on Tuesday, May 5th. Finally, JonesTrading upgraded Editas Medicine from a “hold” rating to a “buy” rating and set a $8.00 target price on the stock in a research note on Tuesday, March 10th. Five research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Editas Medicine presently has an average rating of “Moderate Buy” and a consensus target price of $5.40.

Editas Medicine Price Performance

Shares of Editas Medicine stock opened at $3.08 on Wednesday. The stock has a market cap of $301.55 million, a price-to-earnings ratio of -2.50 and a beta of 2.14. The firm’s 50-day moving average is $2.81 and its 200 day moving average is $2.42. Editas Medicine has a 1 year low of $1.56 and a 1 year high of $4.54.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in EDIT. Captrust Financial Advisors bought a new position in Editas Medicine in the second quarter worth approximately $26,000. StoneX Group Inc. bought a new position in Editas Medicine in the fourth quarter worth approximately $33,000. Abel Hall LLC bought a new position in Editas Medicine in the first quarter worth approximately $36,000. Victory Capital Management Inc. purchased a new position in shares of Editas Medicine during the 3rd quarter valued at about $36,000. Finally, State of Wyoming purchased a new position in shares of Editas Medicine during the 1st quarter valued at about $43,000. 71.90% of the stock is currently owned by institutional investors.

Editas Medicine News Summary

Here are the key news stories impacting Editas Medicine this week:

• Positive Sentiment: Editas said EDIT-401 produced about 90% or greater reductions in LDL-C, Lp(a), and ApoB in non-human primates, reinforcing the program’s potential in hyperlipidemia and cardiovascular risk reduction. Article Title
• Positive Sentiment: The company also said it received positive pre-IND feedback from the FDA and remains on track to submit a clinical trial notification in Australia by mid-2026, which supports progress toward first-in-human data later this year. Article Title
• Neutral Sentiment: Trading was briefly halted for a LULD pause, reflecting elevated volatility around the news. Article Title
• Negative Sentiment: Editas announced a proposed and then priced public offering of 55.6 million shares plus warrants, raising roughly $125 million upfront and potentially more if warrants are exercised; investors often react negatively because the deal increases share count and signals financing needs. Article Title

About Editas Medicine

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.